RED Full risk-off day.
Markets move for reasons
Regime: RED
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| CMPS | $14.89 | 6.05 | 40.30 | Fda: Compass Pathways announced positive 52-week Phase 3 trial results for COMP360 psilocybin treatment showing sustained benefits in treatment-resistant depression, a key milestone toward regulatory appro | — | — |
| ASO | $50.78 | 13.58 | 33.60 | Earnings: Academy Sports (ASO) released Q2 2026 earnings results, which appears to be driving intraday trading activity alongside positive performance from other consumer discretionary stocks. | — | — |
| SSL | $14.62 | 9.94 | 37.65 | Analyst: BofA upgraded Sasol to Buy on a stronger cash flow outlook [via web] | — | — |
| AMBA | $67.04 | 5.61 | 35.36 | Other: No specific catalyst for AMBA identified; headline mentions Caleres earnings and groups AMBA with other stocks moving higher without detailing AMBA-specific news. | — | — |
| ZSL | $24.46 | 3.29 | 27.66 | No catalyst identified | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| CMPS | $14.89 | $14.07 | 3:20 PM | Shadow | $-550.22 | -5.51 | Fda: Compass Pathways announced positive 52-week Phase 3 trial results for COMP360 psilocybin treatment showing sustained benefits in treatment-resistant depression, a key milestone toward regulatory appro | |
| ASO | $50.78 | $53.67 | 3:20 PM | Shadow | $566.44 | 5.69 | Earnings: Academy Sports (ASO) released Q2 2026 earnings results, which appears to be driving intraday trading activity alongside positive performance from other consumer discretionary stocks. | |
| SSL | $14.62 | $14.68 | 3:20 PM | Shadow | $37.57 | 0.38 | Analyst: BofA upgraded Sasol to Buy on a stronger cash flow outlook [via web] | |
| AMBA | $67.04 | $67.71 | 3:20 PM | Shadow | $99.83 | 1.00 | Other: No specific catalyst for AMBA identified; headline mentions Caleres earnings and groups AMBA with other stocks moving higher without detailing AMBA-specific news. | |
| ZSL | $24.46 | $25.07 | 3:20 PM | Shadow | $246.84 | 2.47 | No catalyst identified |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| CMPS | $14.89 | $14.07 | 3:20 PM | Shadow | $-550.22 | -5.51 | LOSS | Fda: Compass Pathways announced positive 52-week Phase 3 trial results for COMP360 psilocybin treatment showing sustained benefits in treatment-resistant depression, a key milestone toward regulatory appro |
| ASO | $50.78 | $53.67 | 3:20 PM | Shadow | $566.44 | 5.69 | WIN | Earnings: Academy Sports (ASO) released Q2 2026 earnings results, which appears to be driving intraday trading activity alongside positive performance from other consumer discretionary stocks. |
| SSL | $14.62 | $14.68 | 3:20 PM | Shadow | $37.57 | 0.38 | WIN | Analyst: BofA upgraded Sasol to Buy on a stronger cash flow outlook [via web] |
| AMBA | $67.04 | $67.71 | 3:20 PM | Shadow | $99.83 | 1.00 | WIN | Other: No specific catalyst for AMBA identified; headline mentions Caleres earnings and groups AMBA with other stocks moving higher without detailing AMBA-specific news. |
| ZSL | $24.46 | $25.07 | 3:20 PM | Shadow | $246.84 | 2.47 | WIN | No catalyst identified |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.